





























































Stable Mutant−On its Own
Linear Region Stabilty
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Exploration of conformational B-cell 
epitopes: components to peptide-based vaccines 
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Overview: The idea of using peptides as cost-effective vaccines is an 
interesting approach for the prevention and treatment of many infectious 
diseases and malignant disorders [1-2]. Such peptides can be designed 
synthetically [3] to elicit a response in immune system. 
Approximately 83% of B-cell epitopes are conformational in nature with 
discontinuous regions of the sequence coming together in the 3D fold of 
the protein and it is therefore important to study how well synthetic 
peptides are able to mimic these conformations. Consequently, we 
characterized B-cell epitopes to inform improved vaccines design and 
allow development of peptide vaccine. 
 
Advantages of peptide vaccines: 
•  Specificity of immune response 
•  Exclusion of undesirable immune response 
•  Improving immunity 
•  Cost effective 
•  Ease of storage/transport 
 
B – Cell Epitope 
Analysis 
MDs on 5 Linear Regions – 1000 ns 
Stability Analysis of Linear Epitope 
Future Directions 
Experimental  validation of the peptide mutant which will involve: 
1.  Protein expression and purification of an antibody 
2.  Characterization of peptide structure by CD 
3.  Antibody peptide binding by SPR 
4.  Testing of peptide as immunogen 
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Epitope Regions 
Shape Classification 
MDs on 5 Folded Regions – 1000 ns 
•  Contacting residues (with antibody) 
•  Contacting and hydrophobic  
•  Non-contacting and hydrophilic  
•  Non-contacting and hydrophobic 
(Targets for making mutations).  
Based on the initial results, from 1000 ns 
simulations of : 
1.  wild type peptide on its own,  
2.  wild type peptide with antibody  
3.  the stabilizing mutant on its own, 
We selected epitopes from 2W9E (linear) and 
4WEB (folded) to perform multiple, shorter 
simulations (500 ns) to study the statistical 
significance of epitope stability.  
MDs were carried out on each of the 
mutant peptide for 500 ns. MDs were 
repeated 10 times to apply statistics on 
the measure of stability. Error bars on 
the data show standard error of mean. 
Conclusions: In this linear epitope, 
mutation M154A in wild type epitope has 
stabilized the mutant to the considerable 
extent as shown in the graphs above. The 
M154A is significantly more stable than the 
wild type (p = 0.0025, Welch t-test) 
Stability Analysis of Folded Epitope 
24 mutant peptides were designed to study the effect of:  
•  End-capping on wild type 
•  Hydrophobic to alanine mutations 
•  Hydrophobic to glutamine mutations 
•  Disulphide stapling on wild type (WTS) 
•  Glycine linker on wild type (WTG) 




Stapling: A) Disulphide stapling in a folded peptide.  
The disulphide bond between two cystiene residues is 
shown in yellow. 
 B) Glycine linker in a folded peptide. 
The torsion angles of glycine and potential positions are 
adjusted to create a peptide bond between glycine and 
one of the potential positions. Extra residues are 
removed from one of the terminus.  
 
Conclusions: 
1. Disulphide bond has stabilized the wild type to its 
best (WTS) 
2. Extending the ends of wild type has also stabilized 
the epitope (WTX) 
3. The cyclisation of wild type by glycine linker has 
also improved the epitope stability (WTG) 
4. All the mutant were stable for 70-98% of the time 
which suggests that the epitope is quite stable. 
 
MDs of 500 ns were carried 
out for each of the mutants. 
The results are shown for 3 
replicas of each peptide’s 
simulation. The aim is to 
perform 10 replicas to 
provide enough sample size 
for statistical evaluation 
between wild type and 
mutant peptides.  
 Epitope residues  
 Non-epitope residues. 
 Cystiene mutations in non-
epitope/potential positions to 
add linker 
 Glycine mutation  
Epitope analyzed as: 
1.  Regions 
2.  Fragments   
Regions: Continuous stretches of sequence 
consisting of at least 3 antibody-contacting 
residues each separated by <= 3 residues)  
Fragment: Antibody-contacting residues that 
do not satisfy the requirements for a region) 
Development 
of a novel 
algorithm 




MD simulations of 
 wild type Linear and 
Folded regions 
Mutant design of 
wild type region  
 
•  End-capping 
•  mutations of 
hydrophobics to  
   alanine and glutamine 
•  Stapling/cyclization 
  
MD simulations of 
mutant peptides 
 
MD simulations of 
 stabilized mutant and wild 
type with antibody 
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